Merck's Bold Move in Delaware

Merck & Co. Inc. has announced a groundbreaking $1 billion investment to establish a new state-of-the-art facility in Delaware. This ambitious project underscores Merck's commitment to innovation and job creation in the pharmaceutical sector.

Revolutionizing Cancer Treatment

The facility will focus on the production of new drugs and an innovative version of Keytruda, Merck's flagship cancer treatment. For the first time, this vital medication will be manufactured within the United States, with production of the injectable version expected to commence by 2030.

A Boost for the US Economy

This initiative is set to generate 4,500 new jobs, marking a significant economic boost for Delaware and the wider US. Merck's investment reflects a growing trend among pharmaceutical giants to bolster US-based production, aligning with national strategies to enhance drug availability and reduce reliance on imports.

"Our strategy ensures that the US can meet its pharmaceutical needs from domestic sources. This move is in perfect harmony with the current administration's objectives and President Trump's vision for the country," stated Rob Davis, Merck's Chief Executive.